Trials / Completed
CompletedNCT02402998
Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia
Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (ESTIT Study) in an Attempt to Achieve Long-term Remission: a Single Arm Multicenter Phase II Clinical and Biological Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A clinical study to evaluate the efficacy of a drug called eltrombopag in adult patients affected of primary immune thrombocytopenia as first treatment to address the disease.
Detailed description
This is a prospective, multicenter phase II trial designed to evaluate the activity of Eltrombopag second line treatment in adult patients with primary Immune Thrombocytopenia (ITP) not responsive or in relapse after a full first line steroids treatment (prednisone or dexamethasone) ± Intravenous Immune Globulin (IVIG).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eltrombopag | Eltrombopag 50 mg/daily. |
Timeline
- Start date
- 2016-02-24
- Primary completion
- 2018-05-22
- Completion
- 2019-08-28
- First posted
- 2015-03-31
- Last updated
- 2021-08-16
Locations
14 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT02402998. Inclusion in this directory is not an endorsement.